Variability of plasmatic levels of big endothelin and NT-proBNP in patients with heart failure in a chronic haemodialysis programme
Authors:
O. Ludka 1; J. Špinar 1; L. Vítovcová 2; D. Sobotová 2; L. Špinarová 3; Z. Pozdíšek 1; V. Musil 1; J. Vítovec 3; J. Tomandl 4
Authors‘ workplace:
Interní kardiologická klinika Lékařské fakulty MU a FN Brno, pracoviště Bohunice, přednosta prof. MUDr. Jindřich Špinar, CSc., FESC
1; II. interní klinika Lékařské fakulty MU a FN u sv. Anny v Brně, přednosta doc. MUDr. Miroslav Souček, CSc.
2; I. interní kardioangiologická klinika Lékařské fakulty MU a FN u sv. Anny Brno, přednosta prof. MUDr. Jiří Vítovec, CSc., FESC
3; Biochemický ústav Lékařské fakulty MU Brno, přednostka prof. RNDr. Eva Táborská, CSc.
4
Published in:
Vnitř Lék 2007; 53(11): 1177-1181
Category:
Original Contributions
Overview
Inter-dialysis variability in levels of big endothelin and NT-proBNP in plasma were studied in 22 patients with established systolic and/or diastolic dysfunction of the left cardiac ventricle assigned to a chronic haemodialysis programme. The plasmatic level of NT-proBNP in all patients was practically unchanged. There was a falling trended between haemodialysis treatments but this was not statistically significant and in absolute values clinically insignificant. Fluctuations were found between individuals but on average all values were stable and high in the pathological range. No significant changes in the plasmatic level of big endothelin were found either. The average levels were again stable and insignificant and the indicated trend did not achieve clinical or statistical significance. The values were once again high in the pathological range. Plasmatic levels of NT-proBNP and big endothelin do not vary according to the phase of the dialysis cycle and mainly reflect the long-term condition of endothelium failure and long-term stress in the left ventricle. Concentrations are not affected by changes in volume or uraemia between dialysis treatments and the suggested trend towards a fall in NT-proBNP and a rise in big endothelin does not have a clear explanation. In any case, this trend remained within the pathological range and is probably not clinically significant.
Key words:
chronic heart failure - haemodialysis - variability - neurohumoral activation
Sources
1. Tomita K, Ujiie K, Nakanishi T et al. Plasma endotelin levels in patients with acute renal failure. N Engl J Med 1989; 321: 1127.
2. Koyama H, Tabata T, Nishzawa Y et al. Plasma endothelin levels in patients with uraemia. Lancet 1989; 1: 991-992.
3. Horký K. Patofyziologická úloha endotelinu u kardiovaskulárních onemocnění a možnosti jeho blokády. Remedia 1998; 6: 408-412.
4. Miyauchi T, Sugishita Y, Yamaguchi I et al. Plasma concentrations of endothelin-1 and endothelin-3 are altered differently in various pathophysiological conditions in humans. J Cardiovasc Pharmacol 1991; 17: 394-397.
5. Saito Y, Kazuwa N, Shirakami G et al. Endothelin in patients with chronic renal failure. J Cardiovasc Pharmacol 1991; 17: 437-439.
6. Koyama H, Tabata T, Nishzawa Y et al. Plasma endothelin levels in patients with uraemia. Lancet 1989; 1: 991-992.
7. Seeberger AO, Ahlborg G, Hemsen A et al. Hemodynamic effects of Endothelin-1 and Big endothelin-1 in chronic hemodialysis patients. J Am Soc Nephrol 1999; 10: 1037-1044.
8. Sudok T, Kangawa K, Minamino N et al. A natriuretic peptide in porcine brain. Nature 1988; 332: 78-81.
9. Cowie MR, Struthers AD, Wood DA et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet 1997; 350: 1349-1353.
10. Struthers AD. Plasma concentration of brain natriuretic peptide. Will this new test reduced the need for cardiac investigations? Br Heart J 1993; 70: 397.
11. Kjohno M, Yasunari K, Yokoawa K et al. Inhibition by atrial and brain natriuretic peptides of endotelin 1 secretion after stimulation with angiotensin II and trobin of cultured human endothelial cells. J Clin Ivest 1991; 87: 1999-2004.
12. Hall C, Rouleau JL, Moye L et al. N-terminal proatrial natriuretic factor. An independent predictor of long term prognosis after myocardial infarction. Circulation 1994; 89: 1934-1942.
13. Tsutamoto T, Maeda Y, Wada A et al. Plasma brain natriuretic peptide concentration as a prognostic predictor in patients with chronic congestive heart failure. Circulation 1993; 88: 321-322.
14. Clarkson PB, Wheeldon NM, McFayden RJ et al. Effects of brain natriuretic peptide on exercise hemodynamics and neurohormones in isolated diastolic heart failure. Circulation 1996; 93: 2037-2042.
15. Wahl HG, Graf S, Renz H et al. Elimination of the Cardiac Natriuretic Peptides B-Type Natriuretic Peptide (BNP) and N-Terminal proBNP by Hemodialysis. Clinical Chemistry 2004; 50: 1071-1074.
16. Cataliotti A, Malatino LS, Jougasaki M. Circulating natriuretic peptide concentration in patiens with end-stage renal disease: role of brain natriuretic peptide as a biomarker for ventricular remodeling. Mayo Clin Proc 2001; 76: 1111-1119.
17. Fagugli RM, Palubo B, Ricciardi D et al. Assotiation between Brain Natriuretic Peptide and Extracellular Water in Hemodialysis Patiens. Nephron Clin Pract 2003; 95: 60-66.
18. Lee SW, Song JH, Kim GA et al. Plasma Brain Natriuretic Peptide Concentration on Assessment of Hydratation status in Hemodialysis Patient. Am J Kidney Dis 2003; 41: 1257-1266.
19. Akiba T, Tachibana K, Togashi K et al. Plasma human brain natriuretic peptide in chronic heart failure. Clin Nephrol 1995; 44: 61-64.
20. Hishizaka Y, Yamamoto Y, Fukunaga T et al. Plasma concentartion of human brain natriuretic peptide in patients on hemodialysis. Am K Kidney Dis 1994; 24: 461-472.
21. Haugh C, Metzele A, Steffgen J et al. Increased brain natriuretic peptide and atrial natriuretic peptide plasma concentrations in dialysis dependent chronic renal failure and in patients with elevated left ventricular filling pressure. Clin Invest 1994; 72: 430-434.
22. Haugh C, Metzele A, Steffgen J et al. Changes in brain natriuretic peptide and atrial natriuretic peptide plasma concentrations during hemodialysis in patients with chronic renal failure. Horm Metab Res 1994; 26: 246-249.
23. Naganuma T, Sugimura K, Wada S et al. The prognostic role of brain natriuretic peptide in hemodialysis patients. Am J Nephrol 2002; 22: 437-444.
24. Lang CC, Choy AM, Henderson IS et al. Effect of hemodialysis on plasma levels of brain natriuretic peptide in patients with chronic renal failure. Clin Sci 1992; 82: 127-131.
25. Kohse KP, Feifel K, Mayer-Werstein R Differential regulation of brain and atrial natriuretic peptides in hemodialysis patients. Clin Nephrol 1993; 40: 83-90.
26. Ishikura F, Ando Y, Park YD et al. Changes of plasma atrial and brain natriuretic peptide levels during hemodialysis. Ren Fail 1996; 18: 261-270.
27. Wahl HG, Graf S, Renz H et al. Elimination of the Cardiac Natriuretic Peptides B-Type Natriuretic Peptide (BNP) and N-Terminal proBNP by Hemodialysis. Clinical Chemistry 2004; 50: 1071-1074.
28. Racek J, Kralova H, Trefil L et al. Brain natriuretic peptide and N-terminal proBNP in chronic hemodialysis patients. Nephron Clin Pract 2006; 103: 162-172.
29. Yasue H, Yoshimura M, Sumida H Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 1994; 90: 195-203.
30. Nishikimi T, Yoshihara F, Morimoto A Relationship between left ventricular geometry and natriuretic peptide levels in essential hypertension. Hypertension 1996; 28: 22-30.
Labels
Diabetology Endocrinology Internal medicineArticle was published in
Internal Medicine
2007 Issue 11
Most read in this issue
- Superior vena cava syndrome (definition, aetiology, physiology, symptoms, diagnosis and treatment)
- Rituximab (MabThera®) – a new biological medicine in rheumatoid arthritis therapy
- Diagnostic benefit of the use of implanted loop recorder (Reveal Plus) for patients with syncope with unclear aetiology
- Endoscopic diagnosis and treatment of biliary complications after laparoscopic cholecystectomy